The effects of glycation on the binding of human serum albumin to warfarin and l-tryptophan

K. S. Joseph, David S Hage

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Diabetes leads to elevated levels of glucose in blood which, in turn, can lead to the non-enzymatic glycation of serum proteins such as human serum albumin (HSA). It has been suggested that this increase in glycation can alter the ability of HSA to bind to drugs and other small solutes. This study used high-performance affinity chromatography (HPAC) to see if there is any significant change related to glycation in the binding of HSA to warfarin and l-tryptophan, which are often used as probe compounds for Sudlow sites I and II of HSA in drug binding studies with this protein. It was found through frontal analysis studies that both of these compounds gave a good fit to a single-site binding model with glycated HSA under the conditions used in this study. There was no significant change in the association equilibrium constants or specific activities for warfarin with HSA at pH 7.4 and 37 °C under glycation conditions that were representative of those expected in pre-diabetes or diabetes, but a 4.7- to 5.8-fold increase in binding affinity for l-tryptophan with glycated HSA was observed. These results indicate that warfarin and l-tryptophan can be successively used as site-selective probes for glycated HSA; however, changes in the affinity of l-tryptophan may need to be considered in such an application. These results should be valuable in future competition studies using these compounds as probes to examine the interactions of other drugs and solutes with Sudlow sites I and II and to determine how changes in HSA glycation can affect the serum protein binding of various pharmaceutical agents during diabetes.

Original languageEnglish (US)
Pages (from-to)811-818
Number of pages8
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume53
Issue number3
DOIs
StatePublished - Nov 1 2010

Fingerprint

Warfarin
Serum Albumin
Tryptophan
Medical problems
Pharmaceutical Preparations
Blood Proteins
Affinity chromatography
Equilibrium constants
Drug Interactions
Affinity Chromatography
Protein Binding
Blood Glucose
Blood
Thermodynamic properties
Binding Sites
Association reactions
Glucose

Keywords

  • Drug-protein binding
  • Glycation
  • Human serum albumin
  • L-Tryptophan
  • Warfarin

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

The effects of glycation on the binding of human serum albumin to warfarin and l-tryptophan. / Joseph, K. S.; Hage, David S.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 53, No. 3, 01.11.2010, p. 811-818.

Research output: Contribution to journalArticle

@article{dc9efd7e184b48d29ae8f45a41af8a10,
title = "The effects of glycation on the binding of human serum albumin to warfarin and l-tryptophan",
abstract = "Diabetes leads to elevated levels of glucose in blood which, in turn, can lead to the non-enzymatic glycation of serum proteins such as human serum albumin (HSA). It has been suggested that this increase in glycation can alter the ability of HSA to bind to drugs and other small solutes. This study used high-performance affinity chromatography (HPAC) to see if there is any significant change related to glycation in the binding of HSA to warfarin and l-tryptophan, which are often used as probe compounds for Sudlow sites I and II of HSA in drug binding studies with this protein. It was found through frontal analysis studies that both of these compounds gave a good fit to a single-site binding model with glycated HSA under the conditions used in this study. There was no significant change in the association equilibrium constants or specific activities for warfarin with HSA at pH 7.4 and 37 °C under glycation conditions that were representative of those expected in pre-diabetes or diabetes, but a 4.7- to 5.8-fold increase in binding affinity for l-tryptophan with glycated HSA was observed. These results indicate that warfarin and l-tryptophan can be successively used as site-selective probes for glycated HSA; however, changes in the affinity of l-tryptophan may need to be considered in such an application. These results should be valuable in future competition studies using these compounds as probes to examine the interactions of other drugs and solutes with Sudlow sites I and II and to determine how changes in HSA glycation can affect the serum protein binding of various pharmaceutical agents during diabetes.",
keywords = "Drug-protein binding, Glycation, Human serum albumin, L-Tryptophan, Warfarin",
author = "Joseph, {K. S.} and Hage, {David S}",
year = "2010",
month = "11",
day = "1",
doi = "10.1016/j.jpba.2010.04.035",
language = "English (US)",
volume = "53",
pages = "811--818",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The effects of glycation on the binding of human serum albumin to warfarin and l-tryptophan

AU - Joseph, K. S.

AU - Hage, David S

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Diabetes leads to elevated levels of glucose in blood which, in turn, can lead to the non-enzymatic glycation of serum proteins such as human serum albumin (HSA). It has been suggested that this increase in glycation can alter the ability of HSA to bind to drugs and other small solutes. This study used high-performance affinity chromatography (HPAC) to see if there is any significant change related to glycation in the binding of HSA to warfarin and l-tryptophan, which are often used as probe compounds for Sudlow sites I and II of HSA in drug binding studies with this protein. It was found through frontal analysis studies that both of these compounds gave a good fit to a single-site binding model with glycated HSA under the conditions used in this study. There was no significant change in the association equilibrium constants or specific activities for warfarin with HSA at pH 7.4 and 37 °C under glycation conditions that were representative of those expected in pre-diabetes or diabetes, but a 4.7- to 5.8-fold increase in binding affinity for l-tryptophan with glycated HSA was observed. These results indicate that warfarin and l-tryptophan can be successively used as site-selective probes for glycated HSA; however, changes in the affinity of l-tryptophan may need to be considered in such an application. These results should be valuable in future competition studies using these compounds as probes to examine the interactions of other drugs and solutes with Sudlow sites I and II and to determine how changes in HSA glycation can affect the serum protein binding of various pharmaceutical agents during diabetes.

AB - Diabetes leads to elevated levels of glucose in blood which, in turn, can lead to the non-enzymatic glycation of serum proteins such as human serum albumin (HSA). It has been suggested that this increase in glycation can alter the ability of HSA to bind to drugs and other small solutes. This study used high-performance affinity chromatography (HPAC) to see if there is any significant change related to glycation in the binding of HSA to warfarin and l-tryptophan, which are often used as probe compounds for Sudlow sites I and II of HSA in drug binding studies with this protein. It was found through frontal analysis studies that both of these compounds gave a good fit to a single-site binding model with glycated HSA under the conditions used in this study. There was no significant change in the association equilibrium constants or specific activities for warfarin with HSA at pH 7.4 and 37 °C under glycation conditions that were representative of those expected in pre-diabetes or diabetes, but a 4.7- to 5.8-fold increase in binding affinity for l-tryptophan with glycated HSA was observed. These results indicate that warfarin and l-tryptophan can be successively used as site-selective probes for glycated HSA; however, changes in the affinity of l-tryptophan may need to be considered in such an application. These results should be valuable in future competition studies using these compounds as probes to examine the interactions of other drugs and solutes with Sudlow sites I and II and to determine how changes in HSA glycation can affect the serum protein binding of various pharmaceutical agents during diabetes.

KW - Drug-protein binding

KW - Glycation

KW - Human serum albumin

KW - L-Tryptophan

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=77954863429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954863429&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2010.04.035

DO - 10.1016/j.jpba.2010.04.035

M3 - Article

VL - 53

SP - 811

EP - 818

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 3

ER -